RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Recruiting

Phase 2

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Sponsor:

Masonic Cancer Center, University of Minnesota

Code:

NCT04105270

Conditions

Adenocarcinoma of Lung

Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Oral Restorative Microbiota Therapy (RMT) Capsules

Durvalumab 1500 mg IV

Cisplatin/pemetrexed or Carboplatin/pemetrexed

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota on 2025-01-20.